Previous 10 |
home / stock / sfosf / sfosf news
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million. Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical-stage assets and one preclinical platform in China. Zai Lab of Shanghai has dosed the first patient in...
Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion. Fosun Pharma of Shanghai closed its $182 million in-licensing of China rights to balixafortide with Switzerland's Polyphor AG. Shanghai's I-Mab reported China...
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares. Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel The...
Since the beginning of the pandemic, AstraZeneca (NYSE:AZN) was among the likely winners in the COVID-19 vaccine race. The company has joined forces with the University of Oxford to develop its candidate, AZD1222. But investors recently got a bitter reminder of the difficulties and risks of clin...
Deals and Financings Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million (see story ). Focused on oncology, Antengene has 12 projects in its portfolio, a mix of in-licensed drugs and in-house R&D ...
Fosun Pharma donates antimalarial medicines to Zambia Ministry of Health and its platform, Chongqing Pharmaceutical Research Institute Co., Ltd., received funding from the Bill & Melinda Gates Foundation to research and develop a large scale semi-synthetic artemisinin process HONG KONG, ...
News, Short Squeeze, Breakout and More Instantly...
Shanghai Fosun Pharmaceutical Co. Ltd. Company Name:
SFOSF Stock Symbol:
OTCMKTS Market:
The whole world is coming together go fight the invisible enemy called COVID-19. Moreover, the quest for a vaccine is revolutionizing the controversial Big Pharma. Nearly 200 are in development, 39 in human clinical trials and nine in Phase III trials. That is quite something, especially co...
Since the beginning of the pandemic, AstraZeneca (NYSE:AZN) was among the likely winners in the COVID-19 vaccine race. The company has joined forces with the University of Oxford to develop its candidate, AZD1222. But investors recently got a bitter reminder of the difficulties and risks of clin...
Fosun Pharma donates antimalarial medicines to Zambia Ministry of Health and its platform, Chongqing Pharmaceutical Research Institute Co., Ltd., received funding from the Bill & Melinda Gates Foundation to research and develop a large scale semi-synthetic artemisinin process HONG KONG, ...